Qiagen (NYSE:QGEN) Rating Lowered to “Equal Weight” at Barclays

Qiagen (NYSE:QGEN) was downgraded by equities researchers at Barclays from an “overweight” rating to an “equal weight” rating in a report released on Tuesday, Marketbeat reports. They presently have a $44.00 target price on the stock. Barclays‘s target price points to a potential upside of 5.72% from the company’s current price.

QGEN has been the subject of several other reports. Stifel Nicolaus set a $50.00 price objective on Qiagen and gave the stock a “hold” rating in a research note on Friday, February 6th. Zacks Research downgraded Qiagen from a “hold” rating to a “strong sell” rating in a research note on Monday, March 9th. Weiss Ratings reissued a “hold (c)” rating on shares of Qiagen in a research note on Friday, March 27th. Wall Street Zen downgraded Qiagen from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. Finally, Robert W. Baird set a $53.00 price objective on Qiagen in a research note on Friday, February 6th. Four equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $53.64.

Qiagen Trading Down 0.3%

Shares of NYSE QGEN opened at $41.62 on Tuesday. Qiagen has a 12 month low of $38.79 and a 12 month high of $57.81. The company has a market cap of $8.58 billion, a price-to-earnings ratio of 20.64, a P/E/G ratio of 2.16 and a beta of 0.79. The company has a quick ratio of 3.31, a current ratio of 3.90 and a debt-to-equity ratio of 0.44. The business has a fifty day simple moving average of $44.44 and a 200-day simple moving average of $47.57.

Qiagen (NYSE:QGEN) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $0.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.61 by $0.01. The firm had revenue of $540.42 million during the quarter, compared to the consensus estimate of $528.53 million. Qiagen had a return on equity of 14.56% and a net margin of 20.33%.The business’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.61 EPS. Qiagen has set its FY 2026 guidance at 2.500- EPS and its Q1 2026 guidance at 0.540- EPS. Sell-side analysts predict that Qiagen will post 2.26 EPS for the current year.

Institutional Investors Weigh In On Qiagen

Hedge funds and other institutional investors have recently made changes to their positions in the company. Danske Bank A S purchased a new stake in shares of Qiagen during the 3rd quarter worth about $36,000. Smartleaf Asset Management LLC increased its holdings in shares of Qiagen by 1,383.3% during the 3rd quarter. Smartleaf Asset Management LLC now owns 890 shares of the company’s stock valued at $39,000 after acquiring an additional 830 shares during the last quarter. Manchester Capital Management LLC acquired a new position in shares of Qiagen during the 4th quarter valued at about $42,000. Global Retirement Partners LLC increased its holdings in shares of Qiagen by 279.9% during the 4th quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock valued at $52,000 after acquiring an additional 851 shares during the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of Qiagen by 375.5% during the 3rd quarter. GAMMA Investing LLC now owns 1,241 shares of the company’s stock valued at $55,000 after acquiring an additional 980 shares during the last quarter. 70.00% of the stock is owned by hedge funds and other institutional investors.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.